Evidence mapPaperPMID 36014373Full record

ArticleMolecules (Basel, Switzerland)2022

Computer-Aided Screening of Phytoconstituents from

Harshit Sajal, Shashank M Patil, Ranjith Raj, Abdullah M Shbeer, Mohammed Ageel, Ramith Ramu

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides.Current protein & peptide science · 2024
    Review
  10. Article
  11. Fermented sugarcane juice-derived probioticFrontiers in microbiology · 2024
    Article
  12. Article
  13. Anti-Glucotoxicity Effect of PhytoconstituentsInternational journal of molecular sciences · 2023
    Review
  14. Article
  15. Article
  16. Screening for potential novel probioticFrontiers in microbiology · 2023
    Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Harshit SajalDepartment of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysuru 570015, India.
Shashank M PatilDepartment of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysuru 570015, India.ORCID 0000-0002-7538-311X
Ranjith RajDepartment of Pharmacology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru 570015, India.
Abdullah M ShbeerDepartment of Surgery, Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-1944-8388
Mohammed AgeelDepartment of Surgery, Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia.
Ramith RamuDepartment of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysuru 570015, India.
JSS Academy of Higher Education and Research · INJazan University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus is a major global health concern in the current scenario which is chiefly characterized by the rise in blood sugar levels or hyperglycemia. In the context, DPP4 enzyme plays a critical role in glucose homeostasis. DPP4 targets and inactivates incretin hormones such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) as physiological substrates, which are essential to regulate the amount of insulin that is secreted after eating. Since the inactivation of incretins occurs, the hyperglycemic conditions continue to rise, and result in adverse physiological conditions linked with diabetes mellitus. Hence, inhibition of DPP4 has been the center of focus in the present antidiabetic studies. Although few DPP4 inhibitor drugs, such as alogliptin, saxagliptin, linagliptin, and sitagliptin, are available, their adverse effects on human metabolism are undeniable. Therefore, it becomes essential for the phytochemical intervention of the disease using computational methods prior to performing in vitro and in vivo studies. In this regard, we used an in-silico approach involving molecular docking, molecular dynamics simulations, and binding free energy calculations to investigate the inhibitory potential of

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHyperglycemiaComputersDipeptidyl Peptidase 4Gastric Inhibitory PolypeptideHumansHypoglycemic AgentsIncretinsMolecular Docking SimulationMolecular Dynamics SimulationOcimum sanctumDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDPP4 protein, humanGastric Inhibitory PolypeptideHypoglycemic AgentsIncretins1S-α-pinenebinding free energy calculationsdehydro-p-cymeneDPP4 inhibitionin silico approachmolecular dockingmolecular dynamics simulationsOcimum tenuiflorumβ-pinene

Identifiers

PMID36014373
PMCPMC9415412
OpenAlexW4291670245

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.